Q-omics provides the consensus-scored EDA2R profile across patient tissues and cancer cell-line models. EDA2R expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EDA2R is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, EDA2R RNA expression shows 18,500 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where EDA2R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EDA2R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EDA2R survival associations across molecular data types. EDA2R RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EDA2R RNA expression–survival associations across cancer types. High EDA2R expression shows unfavorable associations in CESC, HNSC, SCLC and UVM, but favorable associations in KIRC and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EDA2R RNA expression.
This table summarizes EDA2R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for EDA2R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EDA2R shows lower tumor expression in LUSC and BRCA and higher tumor expression in KIRC, KIRP, THCA and LIHC. The KIRC box plot shows higher EDA2R RNA expression in tumor versus normal tissue (log2 FC = +2.142, t-test p < 0.001).
This table shows molecular features associated with EDA2R in patient tissues and cancer cell lines. In patient samples, EDA2R shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, EDA2R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
